Photocure

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Our mission is to develop efficient and innovative treatments and services to improve the lives of our patients and make healthcare more accessible.

Our vision is to become a leading player in the specialty pharmaceutical market, delivering groundbreaking treatments and technologies to enhance the well-being of patients worldwide.

Photocure has been the recipient of several awards, among them the Norwegian Export Prize for its innovative anticancer technology, the World Economic Forum’s Technology Pioneers Award, and the Deloitte Technology Fast 500 Award for its work in specialty pharmaceuticals.